Resveratrol has been reported to be beneficial against diabetes complications. The objective of this study was to evaluate the efficacy of resveratrol in decreasing hyperglycemia in patients with type 1 diabetes (T1D) by a preliminary investigation designed as an exploratory clinical trial. Thirteen patients with T1D from both the sexes participated in this trial. All patients received resveratrol in 500 mg capsules, twice daily for 60 days. Bodyweight, fasting blood sugar (FBS), hemoglobin A1c (HbA1c), insulin, homeostasis model of assessment for insulin resistance (HOMA-IR), homeostasis model of assessment for β-cell function (HOMA-β), and markers of liver and kidney damage, inflammation, and oxidative stress were measured before the intervention, at 30 days and at 60 days. Resveratrol supplementation for 60 days significantly decreased FBS and HbA1c in comparison with the baseline values. Resveratrol treatment also resulted in a decrease in the level of a marker for oxidative stress, malondialdehyde, and an increase in total antioxidant capacity in T1D patients. Insulin, HOMA-IR, HOMA-β, and markers of liver and kidney function and inflammation were not significantly affected by resveratrol treatment. Overall, the results showed that 60 days of resveratrol supplementation exerted strong antidiabetic and antioxidant effects in patients with T1D.

Hypertension is a global health concern for which novel treatment strategies are necessary. The aim of this study is to evaluate the efficacy of resveratrol (trans-3, 5, 4′-trihydroxystilbene, a polyphenol present in grapes) in controlling blood pressure in participants diagnosed with prehypertension and stage 1 hypertension. In a randomized, crossover, double-blinded, placebo-controlled study, 50 participants with prehypertension (diastolic blood pressure and systolic blood pressure, 80–89 mmHg and 120–139 mmHg, respectively) and 50 participants with stage 1 hypertension (diastolic and systolic, 90–99 mmHg and 140–159 mmHg, respectively) will be assigned to receive resveratrol (99 % pure, from Biotivia Longevity Bioceuticals LLC Company, USA, in 500 mg capsules, twice daily for 4 weeks, orally) or placebo (500 mg neutral microcellulose capsules, twice daily for 4 weeks) in a 2 × 2 crossover design (4 weeks treatment—4 weeks washout—4 weeks treatment). The blood pressure of each participant will be recorded (a mean of two times within a 15-minute interval) every week during the study. The participants in the prehypertensive group will not receive any medication, while those in the stage 1 hypertensive group will continue to receive their routine medications during the study. Blood samples will be taken from all groups and examined for various biochemical parameters. This trial will help to establish whether resveratrol is an effective antihypertensive agent in prehypertensive and stage 1-hypertensive patients. The trial outcome will provide novel insight into the clinical efficacy of resveratrol and provide valuable information for conducting future clinical studies with resveratrol. Iranian Registry of Clinical Trials, IRCT201407078129N7. Registered on 15 August 2014.

This study aimed to assess the effect of oral melatonin consumption on improving heart function and reducing postoperative complications in patients undergoing coronary artery bypass grafting (CABG) surgery. A total of 60 CABG patients in the postoperative period were included in this randomized, double-blind, placebo-controlled trial. The patients were divided into three groups: Group 1 (n = 20, 5 mg melatonin), Group 2 (n = 20, 10 mg melatonin), and the placebo group (n = 20). The patients were discharged about 8 to 10 days after the surgery. Blood samples were taken from all the patients before and after the intervention (for 60 days), and Biochemical parameters including creatine kinase-MB (CK-MB), lactate dehydrogenase (LDH), malondialdehyde (MDA), tumor necrosis factor alpha (TNF-α), total antioxidant capacity (TAC), nitric oxide (NO) assessed. Echocardiography and the measurement of systolic and diastolic blood pressure were also performed on participants. Our results showed that melatonin treatment significantly increased the ejection fraction (%EF) and TAC levels in both the treatment groups compared to the placebo group (P < 0.05). Moreover, the levels of inflammatory and oxidative biomarkers, including TNF-α, MDA, and NO, decreased in the intervention group significantly (P < 0.05). In the placebo group, %EF decreased significantly (P = 0.042), while MDA increased (P < 0.001) and TAC decreased (P = 0.002). No significant changes were observed in LDH and CK-MB levels. The comparison of serum biomarkers between the two treatment groups showed that 10 mg of melatonin was more effective than 5 mg, but the difference was not significant (P > 0.05). The present study showed that as a potential antioxidant, melatonin could alleviate oxidative stress and inflammation associated with CABG and is essential in improving overall heart function. Trial registration: IRCT20111119008129N14, first trial registration date: 01/08/2023.

Hypertension is a debilitating disease affecting the population worldwide. Novel therapeutic strategies that complement the current management of hypertension will reduce the disease burden. Our randomized, cross-over, double-blinded, placebo-controlled trial studied the efficacy of plant polyphenol resveratrol (trans-3, 5, 4′-trihydroxystilbene) in managing blood pressure in pre-hypertensive and stage-1-hypertensive patients. Participants with pre-hypertension (diastolic and systolic blood pressure (BP), 80–89 mmHg and 120–139 mmHg, respectively) and 30 participants with stage-1-hypertension (diastolic and systolic BP, 90–99 mmHg and 140–159 mmHg, respectively) were assigned to receive 500 mg resveratrol, twice daily for 4 weeks, orally) or placebo twice daily for 4 weeks) in a 2 × 2 cross-over design (4 weeks treatment—4 weeks washout—4 weeks treatment). The BP of each participant was recorded every week during the study. Data analysis using the multivariable model revealed that resveratrol’s effects on systolic and diastolic BP were not statistically significantly superior to those of placebo. Nitric oxide (NO) was considerably higher in the resveratrol-treated group than in the placebo-treated group. In this preliminary study, Resveratrol supplementation for a short duration enhances nitric oxide production but does not significantly lower blood pressure in pre-hypertension or stage 1 hypertension patients. This finding remains exploratory and needs confirmation through larger, long-term clinical trials. Trial registration: IRCT201407078129N7, first trial registration date: 15/08/2014.

Allergic rhinitis (AR) is a prevalent disease affecting the quality of life of patients throughout the world. This study aimed to assess the prevalence of AR and its association with chronic rhinosinusitis (CRS) in the adult population living in Bushehr, southwestern part of Iran. In this population-based study, a total of 5420 individuals aged 15-65 years were selected through a multi-stage, cluster, random sampling method from which 5201 of them completed the Global Allergy and Asthma Network of Excellence (GA2LEN) questionnaire (Response rate=96.1%). The prevalence of AR, based on Allergic Rhinitis and Its Impact on Asthma (ARIA) classification (mild or moderate; intermittent or persistent) was calculated and the association of AR and CRS was evaluated using a multiple logistic regression model. The overall prevalence of AR was 28.8%, and for the intermittent and persistent AR were 25.9% (out of which 81.34% were moderate to severe) and 74.1% respectively. Moreover, the prevalence of AR was significantly higher in health workers and smokers (p=0.002 and p<0.001, respectively). Furthermore, an association was found between AR and CRS (p<0.001, aOR: 4.68, 95%CI: 4.07-5.39), and also, between the persistent AR and CRS as compared with the intermittent (p<0.001, aOR: 4.21, 95%CI: 3.40-5.22). The present study showed that the prevalence of AR in Bushehr (Southwestern part of Iran) was significantly high. In addition, the results indicated a strong association between AR and CRS, especially in individuals with moderate to severe persistent AR.